• Travere outlined a growth plan centered on FILSPARI expansion in rare kidney disease, targeting a U.S. peak sales opportunity above $3 billion.
• FILSPARI momentum highlighted by U.S. net sales of $141 million in 2Q26, supported by 2,012 new patient start forms, up 96%.
• Strategy assumes continued IgAN demand, accelerated adoption in FSGS following FDA clearance for patients aged 8 and older without nephrotic syndrome.
• Pegtibatinase positioned as a potential first disease-modifying therapy for classical HCU, with pivotal Phase 3 HARMONY topline data expected in 2H27.
• Civorebrutinib presented as a new growth platform with multi-indication potential in immune-mediated kidney diseases, including primary membranous nephropathy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.